Casey Cosgrove, MD, a fellow at the Ohio State Comprehensive Cancer Center, discussed a pilot trial that screened patients with endometrial cancers for Lynch syndrome.The potential impact of this study could lead to the prevention of endometrial, ovarian, and colorectal cancers in the future, Cosgrove said.
Casey Cosgrove, MD, a fellow at the Ohio State Comprehensive Cancer Center, discussed a pilot trial that screened patients with endometrial cancers for Lynch syndrome.The potential impact of this study could lead to the prevention of endometrial, ovarian, and colorectal cancers in the future, Cosgrove said.
With over 60,000 cases of endometrial cancers occurring per year, screening has been recommended by several organizations. In this pilot study, Cosgrove completed testing on all endometrial patients at Ohio State by using immunohistochemistry and microsatellite stability testing.
If patients were found positive for Lynch syndrome, they then underwent germline testing to investigate whether or not the patient was born with the disease or not. Tumor testing was used to consolidate findings if the reason for mutations did not appear in the previous screenings.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More